|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,500 KRW | -1.41% |
|
-6.04% | -25.05% |
Infectex (Russia) has entered into a licensing agreement with Qurient over the latter's investigational tuberculosis (TB) drug Q203. Infectex gained the exclusive rights for the development and commercialisation of Q203 in Russia, Ukraine and Commonwealth of Independent States (CIS). The company intends to continue the pre-clinical studies, and expects to commence clinical trials in 2015.
The financial details of the agreement were not disclosed.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.05% | 85M | |
| +26.64% | 75.76B | |
| -3.02% | 23.95B | |
| +15.84% | 8.7B | |
| +1.47% | 8.29B | |
| -32.22% | 6.7B | |
| +17.83% | 5.38B | |
| +1.17% | 4.08B | |
| -9.44% | 3.79B | |
| -7.80% | 3.3B |
QURIENT CO., LTD. 
